ANTI-ASTHMA DRUG OTC SWITCHES: DATA ON COURSE OF DISEASE
This article was originally published in The Tan Sheet
Executive Summary
ANTI-ASTHMA DRUG OTC SWITCHES: DATA ON COURSE OF DISEASE would be needed to support an Rx-to-OTC switch application, Nonprescription Drugs Advisory Committee Chairman Randy Juhl, PhD, University of Pittsburgh, concluded during a joint meeting of NDAC and the Pulmonary-Allergy Drugs Advisory Committee on Nov. 14. "I think the questions" raised during committee discussion of OTC marketing of asthma drugs "more revolve around the natural course of asthma than about the drug itself," Juhl commented. "I think those questions at this point are not overcomeable just by the drug itself. We really need to know more about asthma."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning